Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.59 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628211 | 0.91 | HTR1A (0.65) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL5767215 | 0.90 | HTR1A (0.72) | HTR1ASLC6A4DRD2HTR2AHTR6 | |
| SCHEMBL5766825 | 0.89 | HTR1A (0.62) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL5764588 | 0.87 | HTR1A (0.61) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL6625927 | 0.87 | HTR1A (0.58) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL6627003 | 0.86 | HTR1A (0.58) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL6629048 | 0.86 | HTR1A (0.59) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL6629066 | 0.85 | HTR1A (0.67) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL6630467 | 0.85 | HTR1A (0.81) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL6848226 | 0.85 | HTR1A (0.64) | HTR1ASLC6A4DRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381614-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO¬2,3-f|QUINOXALINE | WYETH CORP (US) | 2006-08-02 | — | — | EP | claimed |
| US-6617327-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-09-09 | — | — | US | claimed |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | WYETH | 2002-12-05 | — | — | US | claimed |
| EP-1381614-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO¬2,3-f|QUINOXALINE | WYETH CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7008944-B2 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-Dioxino[2,3-f]quinoxaline | WYETH (US) | 2006-03-07 | — | — | US | disclosed |
| US-20040077652-A1 | Treating obsessive compulsive disorder, panic attacks, sexual disorders, eating disorders, obesity, drug abuse and ethanol or cocaine dependence; anxiolytic agents | WYETH | 2004-04-22 | — | — | US | disclosed |
| US-6617327-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-09-09 | — | — | US | disclosed |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | WYETH | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077652-A1 | Treating obsessive compulsive disorder, panic attacks, sexual disorders, eating disorders, obesity, drug abuse and ethanol or cocaine dependence; anxiolytic agents | OPRD1, DRD1, ADH1A | HTR1A 37/4885SLC6A4 136/4885DRD2 5/4885 |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | OPRD1, OPRK1, DRD2 | HTR1A 31/4885SLC6A4 98/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.